The early feasibility immuno-chemotherapy as single treatment modality for larynx preservation (ICoLP) trial was just it sounds. It enrolled 24 patients who all received upfront cisplatin / docetaxel / pembrolizumab q3 weeks x 2 cycles. Those without radiographic progression (n=24 of 24) completed a total of 4 cycles and then underwent re-biopsy. At this time, 17 of 22 evaluable patients (77%) were deemed to have a complete pathologic response on biopsy and were monitored while the remaining 5 patients moved forward with definitive local therapy with radiation or surgery. Importantly, only 5 of these 17 patients have made it to one year without recurrence with another 6 already requiring salvage local therapy and the remaining being too soon to tell. | Ferrarotto, ASCO 2023
